section name header

Pronunciation

TYE-ka-GREL-or

Classifications

Therapeutic Classification: antiplatelet agents

Pharmacologic Classification: platelet aggregation inhibitors

Indications

BEERS REMS

Action

Therapeutic Effects:

Pharmacokinetics

Absorption: 36% absorbed following oral administration.

Distribution: Well distributed to tissues.

Protein Binding: 99%.

Metabolism/Excretion: Mostly metabolized in the liver by the CYP3A4 isoenzyme, with some metabolism by the CYP3A5 isoenzyme) with conversion to an active metabolite (AR-C124910XX); excretion primarily via biliary secretion; <1% excreted unchanged or as active metabolite in urine.

Half-life: Ticagrelor: 7 hr; Active metabolite: 9 hr.

Time/Action Profile

(inhibition of platelet aggregation)

ROUTEONSETPEAKDURATION
POwithin 30 min4 hr5 days

† Following discontinuation.

Contraind./Precautions

Contraindicated in:

Use Cautiously in:

Adv. Reactions/Side Effects

CV: bradycardia, heart block.

Endo: gynecomastia.

Hemat: BLEEDING.

Resp: dyspnea, central sleep apnea, Cheyne-Stokes respiration.
Misc: (INCLUDING ANGIOEDEMA)HYPERSENSITIVITY REACTIONS .

Interactions

Drug-Drug:

Route/Dosage

Acute Coronary Syndrome or History of Myocardial Infarction

Coronary Artery Disease Without a History of Myocardial Infarction or Stroke

Acute Ischemic Stroke or Transient Ischemic Attack

Availability

(Generic available)

Assessment

Lab Test Considerations:

Implementation

Patient/Family Teaching

Evaluation/Desired Outcomes

US Brand Names

Brilinta